Description
Cancer testing is maturing from personalized medicine to precision medicine, where protein and molecular biomarkers are essential for precise diagnosis, therapy selection, therapy monitoring and early detection of cancer recurrence. The World Market for Cancer Diagnostics, as well as relevant industry merger data provided by Kalorama Information, provides authoritative and complete analysis of the cancer testing industry, with expert market sizing and opportunity assessment.
Segment markets for cancer testing are comprehensively covered in Kalorama Information’s World Market for Cancer Diagnostics. The report contains detailed market data on the following IVD segments for their use in cancer diagnostics:
- Immunoassay – tumor markers
- Molecular – cancer assays
- Molecular – histology
- Molecular – HPV
- CTCs
Critical Need for Prevention Supports a Market for Innovative Diagnostic Tools
Given the unfortunate statistics of cancer in the developed world, innovation is a must. Growth rates in cancer testing tends to be higher than in other IVD fields. Diagnostic tests for effective cancer screening are obviously needed more than ever. As this report goes to print a number of significant developments are taking place in cancer follow up. New imaging tools, bioinformatics, sequencing technologies, improved histological tests are among the trends discussed in this multifaceted report. The importance of this industry is seen in the flurry of investments and financing arrangements made and the number of partnerships and purchases/mergers where one or both companies are involved in cancer diagnostics. This report contains
- Investments and Financing Agreements For Cancer Diagnostics Companies
- Selected Agreements Between Cancer Diagnostic Companies
- Selected Agreements Between Cancer Diagnostic Companies and Other Diagnostic Companies
- Selected Agreements Between Cancer Diagnostic Companies and Pharmaceutical or Biopharmaceutical Companies
- Selected Cancer Diagnostic Company Agreements with Academic or Other Non-Profit Organizations
- Selected Acquisitions of Cancer Diagnostic Companies
Complete Market and Trend Analysis
In five previous editions. Kalorama has defined the oncology testing market, based on primary research of the market with particular attention to important market trends. These trends are more important to understand than today’s numbers. Market analysis in this report covers world markets for in vitro cancer diagnostics, however the reader will find a bias toward the developed areas of the globe — N. America, Japan and Western Europe. However cancer is a growing global problem and where possible the report covers cancer testing in the more industrialized developing countries of Latin America and Asia Pacific.
The phenomenon of test personalization comes under many guises as pharmacogenomic, pharmacogenetic, companion tests, and represents one of the fastest growing segments of the market for cancer tests. It has emerged fully from research into clinical practice. Instrumentation now automates many of the sample preparation and assay steps that were formerly labor intensive. New tests are being launched all the time. Some personalized cancer tests are CE Marked and FDA-cleared and many more are in development. More and more laboratories offer complex panels of tests that help physicians evaluate disease risk and make therapeutic decisions. Government and private healthcare payers have recognized the value of new molecular tools and are agreeing to pay for them.
Unparalleled Review of Cancer Testing Competitors: Top Tier IVD Companies And Specialist Companies
This report is written from the point of view of diagnostic modalities for the detection and management of cancer and in particular solid tumors. The technology to detect cancers of the blood – lymphomas, myelomas and leukemia – is mature and well established. The routine complete blood count screens for blood cell abnormalities and is followed by bone marrow analysis and flow cytometric studies of the blood cell surface markers. These to arrive at a more specific diagnosis. As such this report does not discuss area of hematological cancer diagnosis in great detail.
The emphasis is on in vitro diagnostic tests, however a discussion of the role of diagnostics in cancer management, must include in vitro and in vivo tests. The two are inextricably linked. The same cell markers used in flow cytometry and antibodies used for immunoassays to detect elements of the immunity process are used as vectors for imaging agents to detect tumors and to monitor the extent of cancer metastasis.
In addition to extensive reviews of products on the market and in development in each segment, the report provides detailed company profiles in several sections, including the following companies:
- Abbott Diagnostics
- Agendia BV
- Agilent Technologies
- ARUP Laboratories
- Asuragen Inc.
- Beckman Coulter (Danaher)
- Becton, Dickinson and Company (BD)
- Bio-Rad Laboratories, Inc.
- Biocartis
- Biocept, Inc.
- Biodesix
- bioMérieux Inc.
- BioReference Laboratories
- Biotheranostics, Inc. (Hologic)
- Danaher Corporation
- DiaSorin S.p.A
- Enzo Biochem Inc.
- Epic Sciences
- Epigenomics AG
- Exact Sciences Corp.
- Exosome Diagnostics, Inc
- Foundation Medicine, Inc.
- Guardant Health, Inc.
- Helomics Corporation
- Hologic, Inc.
- Illumina, Inc.
- LabCorp
- Leica Biosystems (Danaher)
- LungLife AI
- Mayo Medical Laboratories
- MDxHealth SA
- Menarini-Silicon Biosystems
- Myriad Genetics, Inc.
- Natera
- NeoGenomics
- OPKO Health, Inc.
- Pacific Biosciences
- Qiagen N.V.
- Quest Diagnostics
- Roche Diagnostics
- Sysmex Corp.
- Thermo Fisher Scientific Inc.
- Trovagene, Inc.
- Ventana Medical Systems (Roche)
- Veracyte
